The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a ...

New Delhi: Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

Vaxcyte has commenced the Phase II trial of its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in healthy infants.

The National Pharmaceutical Pricing Authority (NPPA) has sought expertise from the Indian Patent Office to assist in making ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Objective To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England. Design Longitudinal study.

a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs. We investigated whether a single primary dose and booster dose (1p+1 ...

Abbott on Wednesday announced the launch of its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. According to the company’s statement, Abbott’s PCV-14 valent ...